Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRX167700 monotherapy vs placebo and tramadol in knee osteoarthritis pain
2017-001185-20Phase 2Terminated
- Sponsor
- Proximagen
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PRX167700 in osteoarthritis (OA) (3 arms), sponsored by Proximagen. Primary endpoint: Change in WOMAC Pain Score from baseline to Day 42 (PRX167700 vs placebo). Started Oct 2017; status: terminated.
02
Drugs
PRX167700
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on 2017-001185-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001185-20.